GINA 2015: the latest iteration of a magnificent journey

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

“… Several national or regional plans on asthma, COPD, other chronic respiratory diseases and allergy. Guidelines or strategies for asthma [ 49 – 52 ], COPD [ 53 ], rhinitis [ 21 ], rhinosinusitis [ 54 ] or severe asthma [ 55 ] (Table 5 ). Table 5 An example of scaling up strategy: ARIA (Allergic Rhinitis and its Impact on Asthma) [ 21 , 26 ] Allergic rhinitis is one of the most prevalent diseases in the world (25 % of the European Union population).…”

“…A review on the European asthma plans based on the Finnish Asthma Plan is available [42 ]. The Portuguese National Programme for Respiratory Diseases (PNDR), the first national programme including all respiratory diseases [45 ]. In the Netherlands, the SMART‐formulated collaborative National Action programme against Chronic Lung Diseases (NACL) aims to improve the cost‐effectiveness of respiratory prescribing, while reducing hospitalisation days, productivity loss, adolescent smoking, and mortality due to asthma and COPD. Both the Ministry of Health and the collective Health Insurers Netherlands are funding the programme [13 ]. Several national or regional plans on asthma, COPD, other chronic respiratory diseases and allergy. Guidelines or strategies for asthma [49–52 ], COPD [53 ], rhinitis [21 ], rhinosinusitis [54 ] or severe asthma [55 ] (Table 5 ). Care pathways provided by national institutions (e.g. NICE in the UK, National Institute for Health and Care Excellence or the Haute Autorité de Santé in France, ICP for acute asthma in children in Northern Ireland). The World Health Organization guidelines for asthma and COPD in low‐income settings (WHO PEN) [14 ]. Management plans already successfully tested in low and middle‐income countries [15 ]. A common approach to severe asthma and allergic diseases [17, 19 ]. In Spain, Polibienestar Research Institute is developing a Multi‐Agent Simulator for people requiring prolonged mechanical ventilation based on the validated LTCMAS [64 ] and following the Canadian model [65 ], which is easily replicable and transferrable to other healthcare systems and to other diseases.…”

“…Guidelines or strategies for asthma [49–52 ], COPD [53 ], rhinitis [21 ], rhinosinusitis [54 ] or severe asthma [55 ] (Table 5 ).…”

Dynamic Urinary Proteome Changes in Ovalbumin-Induced Asthma Mouse Model Using Data-Independent Acquisition Proteomics

“…It is characterized by variable symptoms, such as wheeze, dyspnea, and chest tightness and/or cough that vary over time and intensity, together with variable expiratory airflow limitation. 1 Asthma is a major public health concern worldwide, with global prevalence ranging from 1% to 21% in adults 2 and up to 32% in children aged 6–7 years. 3 The predominant mechanism involved in the pathogenesis of asthma is a Type 2 helper T cell (Th2) cytokine-mediated eosinophilic airway inflammation associated with hyper-responsiveness of the lungs.…”

Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children

“… 7 , 8 In this dosing range, side effects are diminished, and there is a less need for chronic monitoring of levels. The most recent iteration of the Global Initiative for Asthma guidelines includes low-dose theophylline as a possible adjunctive outpatient controller therapy, 9 though the 2007 NAEPP guidelines do not make reference to low-dose theophylline specifically. Neither set of guidelines remark on the use of low-dose theophylline for acute status asthmaticus.…”